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ABSTRACT
We investigated whether a polymorphism at nucleotide position
1220, resulting in an asparagine-to-serine change at codon 363 in the
glucocorticoid receptor (GR) gene is associated with an altered sen-
sitivity to glucocorticoids.
In a group of 216 elderly persons, 13 heterozygotes for the N363S
polymorphism were identified by PCR/single strand conformation
polymorphism analysis. In 2 dexamethasone (DEX) suppression tests
(DSTs), using 1 and 0.25 mg DEX, the circulating cortisol and insulin
concentrations were compared between N363S carriers and controls.
In the 1-mg DST, there were no differences between N363S carriers
and controls, with respect to adrenal suppression, but there was a
significantly higher (P , 0.05) insulin response in N363S carriers. In
the 0.25-mg DST, a significantly larger (P , 0.05) cortisol suppression
and higher (P , 0.05) insulin response were seen in N363S carriers.
Comparison of blood pressure, body mass index (BMI), and bone
mineral density (BMD) between the N363S carriers and controls
showed that N363S carriers had a higher (P , 0.05) BMI but normal
blood pressure. There was an obvious trend towards lower age-, BMI-,
and sex-adjusted BMD in the lumbar spine in N363S carriers. GR
characteristics measured in 41 controls and 9 N363S carriers in pe-
ripheral mononuclear leucocytes showed no differences between
N363S carriers and controls, with respect to GR number and ligand
binding affinity. However, there was a trend towards greater sensi-
tivity to DEX in the carriers’ lymfocytes, in a mitogen-induced cell
proliferation assay. In transfection assays, the capacity of the codon
363 variant to activate mouse mammary tumor virus promotor-me-
diated transcription in COS-1 cells was unaltered, when compared
with the wild-type GR.
We conclude that in 6.0% of our study population, a polymorphism
in codon 363 of the GR gene was found. Individuals carrying this
polymorphism seemed healthy at clinical examination but had a
higher sensitivity to exogenously administered glucocorticoids, with
respect to both cortisol suppression and insulin response. Life-long
exposure to the mutated allele may be accompanied by an increased
BMI and a lowered BMD in the lumbar spine but does not affect blood
pressure. (J Clin Endocrinol Metab 83: 144–151, 1998)
THERE IS a considerable variability in the sensitivity toglucocorticoids (GCs) across individuals. Early morn-
ing serum cortisol concentrations show a great diversity
among individuals. On the other hand, there is a marked
individual stability of baseline cortisol concentrations within
persons that is closely related to the feedback sensitivity of
the hypothalamo-pituitary-adrenal-axis to a low dose of
dexamethasone (DEX) (Huizenga et al. 1997, submitted). Ex-
treme examples of variability in sensitivity to GCs are the
cortisol hyperreactive syndrome and cortisol resistance (CR).
In 1990, Iida et al. (1) described a patient who presented with
signs and symptoms of Cushing’s syndrome, in spite of
persistent hypocortisolemia. So far, this is the only case re-
ported with cortisol hyperreactivity. CR is a rare condition,
as well. The first patient was described in 1976 (2), and since
then, only about 10 symptomatic and asymptomatic patients
and family members have been identified (3–5). As early as
15 yr ago, it was suggested that CR might be the result of a
defect in the functional characteristics of the glucocorticoid
receptor (GR). The GR has been cloned and sequenced (6)
and found to be organized into a series of discrete domains
that mediate the receptor functions of hormone-binding,
DNA-binding, and transcriptional modulation (7). The bind-
ing of GCs to the GR induces a series of cellular events that
results in the activation or repression of a network of GC-
responsive genes and produces a specific cellular response
(8). Thus far, the molecular basis of CR has been elucidated
in 4 kindreds (9–12). In all reported cases, mutations in the
hormone-binding domain of the GR-gene seemed to be the
cause of CR. The molecular basis of cortisol hyperreactivity
(1) has not been elucidated yet.
Variability in the sensitivity to GCs is also observed in
patients treated with GCs. GCs are important therapeutic
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agents used for the treatment of various inflammatory and
autoimmune diseases. Although plasma concentrations of
GCs can be ascertained, their functional effects on target
tissues are very difficult to predict (13). In clinical observa-
tions, a considerable variability among subjects is seen in
their sensitivity to GC therapy, both with regard to efficacy
and to the prevalence and severity of side effects.
In a previous study, 2 DEX suppression tests (DSTs) were
performed in 216 elderly individuals, to gain insight into the
sensitivity to GCs in the normal population (Huizenga et al.
1997, submitted). Furthermore, a general screening of the
GR-gene in 40 persons was performed using PCR/SSCP
analysis (14). Based on indications that a previously reported
polymorphism in the 39-region of exon 2 [which encodes for
the transactivation domain of the GR of the GR gene
(Asn363Ser, N363S, Fig. 1C)] might be associated with an
increased sensitivity to GCs (14), we reexamined our study
population for this polymorphism and analyzed whether its
presence was associated with increased GC-sensitivity.
Materials and Methods
For the present study, a sample of participants from the Rotterdam
Study was invited for an additional examination. The Rotterdam Study
is a population-based cohort study of the determinants of chronic dis-
abling diseases in the elderly. All approximately 10,000 inhabitants of a
suburb of Rotterdam, aged 55 yr and over, were invited to participate
as described elsewere (15). The population for the present study in-
cluded 216 persons aged 55 to 80 yr [102 men and 114 women with mean
ages of 67.7 6 5.6 (se) and 65.8 6 6.1 yr, respectively] who had completed
the baseline visit for the Rotterdam Study not more than 6 months
earlier. Subjects with acute, psychiatric, or endocrine diseases, including
diabetes mellitus treated with medication, were not invited. Compared
with other participants of the Rotterdam Study of the same age without
diabetes mellitus, there were no differences in age and gender distri-
bution and cardiovascular risk factors. From all subjects, written in-
formed consent was obtained, and the study was approved by the
Medical Ethics Committee of the Erasmus University Medical School.
Two DSTs were carried out as described previously (Huizenga et al.,
1997, submitted). In brief, participants were seen at the research centre
after an overnight fast. Blood was drawn by venapuncture to determine
serum cortisol and insulin concentrations. Participants were given a
tablet of 1.00 mg DEX and instructed to ingest it at 2300 h. Next morning,
fasting blood samples were obtained at the same time as the previous
morning. In these samples, cortisol, insulin, and DEX concentrations
were measured. Circulating cortisol DEX concentrations were deter-
mined as described previously (Huizenga et al., 1997, submitted). Serum
insulin concentrations were determined using a commercially available
RIA (Medgenix Diagnostics, Brussels, Belgium). Intra- and interassay
variations were 8.0 and 13.7%, respectively.
Two and a half years later, all 216 participants were invited for a
0.25-mg DST; 164 subjects agreed to participate in this second test (76
men and 88 women, with mean ages of 69.1 6 5.9 and 67.6 6 5.6 yr,
respectively). The same procedures were used as described for the 1-mg
FIG. 1. A, PCR/SSCP analysis of the 39-
part of exon II of the GR gene. The anal-
ysis revealed a polymorphism in 13 of
216 elderly individuals (C, control; V,
variant). B, Sequence analysis of the
polymorphism in the 39-part of exon II
of the GR gene, showing a heterozygous
A-to-G point mutation at cDNA position
1220. C, Structure of the human GR
gene and protein and its functional do-
mains (DBD, DNA-binding domain;
HBD, hormone-binding domain), indi-
cating the position of an asparagine-to-
serine change at codon 363, as a result
of the A-to-G point mutation at cDNA
position 1220 of the GR gene.
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DST. In the fasting and post 0.25-mg DEX samples, glucose concentra-
tions were determined using routine standard laboratory methods.
Both as part of the baseline examinations of the Rotterdam Study and
at the second determination, body weight and height were measured to
calculate body mass index (BMI, kg/m2), and sitting blood pressure was
measured at the right upper arm with a random-zero sphygmomanom-
eter. Bone mineral density (BMD) measurements were performed by
dual-energy x-ray absorptiometry using a DPX-L densitometer (Lunar
Radiation Corporation, Madison, WI). Standard positioning was used
with anterior-posterior scans of the lumbar spine and the right proximal
femur. In cases of a history of hip fracture or prothesis implantation, the
left femur was scanned. Using standard software, the vertebrae L2 to L4
and the femoral neck were analyzed. Quality assurance included cali-
bration with the standard of the machine and was performed routinely
every morning. The in vivo coefficient of variation for the BMD mea-
surements was 0.9% in the lumbar spine and 3.2% in the femoral neck
(16).
PCR/SSCP analysis of the GR gene
DNA was isolated from peripheral blood leucocytes of all subjects
using standard techniques. PCR amplification and SSCP analysis of the
39-region of exon 2 of the GR gene were carried out using primer
sequences and amplification and electrophoresis conditions previously
described by Koper et al. (14).
Whole-cell DEX-binding assay and mitogen-induced
proliferation assay
From 41 randomly selected controls and 9 carriers of the N363S
mutation (see Results), 40 mL heparinized blood was drawn for a whole-
cell DEX-binding assay and a mitogen-induced proliferation assay. GR
characteristics in mononuclear leucocytes and the sensitivity of mono-
nuclear leucocytes to the inhibition of phytohemagglutinin-stimulated
incorporation of [3H]-thymidine by DEX were determined as described
previously (3).
Cell culture and transfections
Monkey kidney (COS-1) cells were maintained in DMEM-Ham’s F-12
tissue culture medium (Life Technologies, Gaithersburg, MD), supple-
mented with 5% dextran-coated charcoal-treated FCS (Life Technolo-
gies). For transcription regulation studies, cells were plated at 1.0 3 105
cells/well (10 cm2), grown for 24 h, and transfected overnight by calcium
phosphate precipitation, as described previously (17). Cells were trans-
fected with 250 ng GR expression plasmid and 250 ng reporter plasmid
per well. After transfection, experimental media were added. After an
incubation period of 24 h, cells were harvested for the luciferase (LUC)
assay, as described previously (18).
Statistical analysis
Results are reported as mean 6 se unless otherwise stated. Serum
cortisol, insulin and glucose concentrations, blood pressure, BMI, BMD,
and receptor characteristics were compared between N363S carriers and
controls using Student’s t test. To control for possible confounders, the
analyses were adjusted for BMI, if appropriate, using multiple linear
regression analysis. Values for BMD were expressed as Z-scores (num-
ber of standard deviations below or above the age-, BMI-, and sex-
standardized average value obtained from 2446 males and 3368 females
who participated in the baseline visit for the Rotterdam study) (16).
Results
After the 1-mg DST, 5 individuals were identified with a
post-DEX cortisol concentration .140 nmol/L, which is the
cut-off point for a normal test result in our clinic when the
DST is used for the screening for Cushing’s syndrome. These
5 subjects were further investigated for CR (14) and were left
out of the calculations described here. Screening for the
codon 363 polymorphism was performed using PCR/SSCP
analysis. The abnormal pattern in the 39-fragment of exon 2
was found in 13 individuals out of the whole study popu-
lation of 216 subjects (6.0%, Fig. 1A). Sequence analysis of the
fragment showed an A-to-G point mutation at complemen-
tary DNA (cDNA) position 1220, resulting in an asparagine-
to-serine change at codon 363 (Fig. 1B). The mutation was
found to be heterozygous in all cases.
The subjects without the mutation in codon 363 (controls)
and the 13 persons heterozygous for the polymorphism
(N363S carriers) have been investigated further, with respect
to their hypothalamo-pituitary-adrenal-axis and sensitivity
to GCs.
In vivo results
The group of N363S carriers consisted of four men and
nine women, whereas in the control-group, the sexes were
equally divided. There was one female N363S carrier who
showed an additional mutation in the 59-prime part of exon
2 of the GR gene. She was further investigated for CR (14) and
left out of all comparisons.
At the first examination, no significant difference in age
between the groups was present, as shown in Table 1a. The
TABLE 1a. Age, BMI, and blood pressure at first examination in controls (n 5 198) and N363S carriers (n 5 12)
Controls N363S carriers
P-valuea
Mean SE Mean SE
Age (yr) 66.6 0.44 68.5 1.64 0.28
BMI (kg/m2) 26.6 0.26 28.1 1.09 0.07
Systolic blood pressure (mmHg) 139 1.35 137 7.00 0.77
Diastolic blood pressure (mmHg) 74.9 0.71 73.1 2.84 0.54
a Test for the difference between controls and N363S carriers.
TABLE 1b. Age, BMI, and blood pressure at second examination in controls (n 5 153) and N363S carriers (n 5 8)
Controls N363S carriers
P-valuea
Mean SE Mean SE
Age (yr) 68.3 0.49 69.3 2.36 0.63
BMI (kg/m2) 25.5 0.30 28.3 1.52 0.04
Systolic blood pressure (mmHg) 143 1.50 140 10.7 0.57
Diastolic blood pressure (mmHg) 88.1 0.86 83.7 6.37 0.26
a Test for the difference between controls and N363S carriers.
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N363S carriers had a higher mean BMI, compared with con-
trols, which did not reach statistical significance (P 5 0.07).
Systolic and diastolic blood pressures were not different
between the groups (Table 1a).
At the second examination, 164 of the initial 216 individ-
uals participated, 9 of whom had the codon 363 polymor-
phism. The female N363S carrier with the additional point
mutation in exon 2 was excluded again from the comparison,
and so were 2 subjects who had a post-DEX cortisol con-
centration more than 140 nmol at the first determination
(Table 1b). In the control group, the sexes were equally di-
vided; the group of N363S carriers now consisted of 5 women
and 3 men. At the second examination, the N363S carriers
had a significantly higher BMI, as compared with the control
group (P , 0.04). In the first determination, there was no
statistically significant difference in BMI between controls
and N363S carriers in this subgroup (26.1 6 0.28 in controls
vs. 28.1 6 1.30 in N363S carriers, P 5 0.09). As in the first
examination, there were no differences between the groups,
with respect to systolic or diastolic blood pressure.
Physical examination of the N363S carriers revealed no
evident abnormalities. One male N363S carrier had hyper-
tension, and two females had hyperinsulinemia (fasting in-
sulin . 25 mU/L).
Cortisol concentrations. Table 2a shows the concentrations of
fasting serum cortisol before and after administration of 1 mg
DEX, the DEX concentration, and the cortisol suppression in
reaction to DEX (D cortisol). There were no differences be-
tween the controls and the N363S carriers, either in basal
levels or in response to the administration of 1 mg DEX.
Table 2b provides the same parameters before and after the
administration of 0.25 mg DEX. Again, there were no dif-
ferences in baseline cortisol, but there was a larger decrease
in cortisol concentration (D cortisol) in response to 0.25 mg
DEX in the N363S carriers than in controls (280.5 nmol/L in
controls vs. 373.9 nmol/L in N363S carriers, P , 0.09, un-
adjusted data). This difference in D cortisol was statistically
significant when the data were adjusted for BMI (443.8 in
controls vs. 553.6 in N363S carriers, P , 0.05). Adjusting for
BMI was necessary because there was a statistically signif-
icant difference in BMI between controls and N363S carriers,
and BMI is known to influence the cortisol concentration. The
actual DEX concentrations were equal in both groups (P 5
0.50), so the higher response in the N363S carriers was not
caused by higher DEX concentrations.
Insulin and glucose concentrations. Table 3 shows the fasting
insulin concentrations before and after the administration of
1 and 0.25 mg DEX, respectively, and the increase in insulin
levels in response to DEX administration. To be certain that only
the data from subjects with a normal carbohydrate tolerance
were analyzed, subjects with hyperinsulinemia or diabetes mel-
litus (fasting insulin or glucose concentrations above 25 mU/L
or 7.8 mmol/L, respectively) were excluded from this analysis
(20 controls excluded, n 5 178; and 2 N363S carriers excluded,
n 5 10). There was a significant increase in insulin concentra-
tions in response to the administration of 1 mg DEX among the
remaining 188 subjects (12.9 6 0.53 mU/L before and 19.1 6
0.80 mU/L after DEX administration, respectively, P , 0.001).
There were no significant differences between the groups in
fasting or post-DEX insulin concentrations, but there was a
significantly larger increase in insulin levels in the N363S car-
riers in response to 1 mg DEX (P , 0.01), compared with
controls. As mentioned before, these differences in insulin re-
sponse were not caused by differences in DEX concentrations
between the two groups (Table 2a).
After the administration of 0.25 mg DEX, there was a drop
in insulin concentrations in the controls. In the N363S carriers,
there was a slight increase in insulin concentrations. After com-
parison of the insulin responses to 0.25 mg DEX between the
two groups, again a significantly larger response in the N363S
carriers became apparent (P , 0.03). Glucose levels did not
increase in response to DEX administration, nor were there
differences in glucose concentrations between the two groups.
BMD. In Fig. 2, the mean values and sd for BMD in the
lumbar spine and the femoral neck in controls and N363S
carriers expressed as Z-scores are shown. The figure shows
that in the lumbar spine, there was a trend towards lower
BMD in the N363S carriers, compared with controls (z-scores:
20.48 vs. 0.02 respectively, P 5 0.08). In the femoral neck,
there were no differences in BMD between the two groups
(P 5 0.67).
TABLE 2a. Cortisol and DEX concentrations in controls (n 5 198) and N363S carriers (n 5 12) before and after 1 mg DEX
Controls N363S carriers
P-valuea
Mean SE Mean SE
Fasting cortisol (nmol/l) 513.5 11.1 532.2 32.4 0.49
Post DEX cortisol (nmol/L) 26.26 1.22 25.80 3.45 0.97
D cortisol (nmol/L) 488.1 10.9 506.3 33.5 0.50
DEX (nmol/L) 7.300 0.25 8.500 1.44 0.30
a Test for the difference between controls and N363S carriers, adjusted for BMI.
TABLE 2b. Cortisol and DEX concentrations in controls (n 5 153) and N363S carriers (n 5 8) before and after 0.25 mg DEX
Controls N363S carriers
P-valuea
Mean SE Mean SE
Fasting cortisol (nmol/L) 541.7 12.0 566.5 44.9 0.53
Post DEX cortisol (nmol/L) 261.2 11.4 192.6 38.1 0.13
D cortisol (nmol/L) 280.5 12.6 373.9 37.2 ,0.05
DEX (nmol/L) 2.820 0.13 3.300 0.55 0.48
a Test for the difference between controls and N363S carriers, adjusted for BMI.
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In vitro results
Whole-cell DEX-binding assay and mitogen-induced proliferation
assay
Figure 3 shows the results from 50 whole-cell DEX-binding
assays and mitogen-induced proliferation assays (41 ran-
domly selected controls and 9 N363S carriers). The number
of receptors (n, Fig. 3A) and the dissociation constant (Kd,
Fig. 3B) were not different in both groups (n 5 7056 6 200
in controls, n 5 7242 6 645 in N363S carriers; Kd 5 10.6 6
0.63 in controls, Kd 5 8.5 6 1.14 in N363S carriers, respec-
tively). Also, no statistically significant difference in 50% of
the maximal inhibition (IC50) values between the N363S car-
riers and controls was found; as shown in Fig. 3C, there was
a trend towards a lower IC50 in the N363S carriers (IC50 5
47.7 6 9.6 in controls, IC50 5 21.8 6 6.4 in N363S carriers,
respectively).
Transcriptional activation studies. To investigate whether the
observed codon change at position 363 resulted in an altered
capacity of the GR protein to activate transcription, we co-
transfected a plasmid containing this variant receptor and a
mouse mammary tumor virus (MMTV)-driven LUC reporter
plasmid in COS-1 cells. Cells were incubated with increasing
concentrations of DEX. At DEX concentrations between 0 and
100 nmol/L, the capacity of the N363S variant to activate
transcription from the MMTV promotor of the N363S variant
was unaltered, compared with the wild-type GR (Fig. 4).
Discussion
In this study, we examined differences in the sensitivity to
GCs within a normal elderly population, using DSTs with
two different doses of DEX. In a previous study (14), looking
for mutations in the GR gene that cause the clinical syndrome
of CR (9–12), we found a polymorphism that seemed to be
associated with increased sensitivity to GCs. This polymor-
phism, located at nucleotide position 1220 (AAT to AGT),
results in an asparagine-to-serine change in codon 363 of the
GR protein. This polymorphism was heterozygously present
in 13 of the 216 subjects. One of these subjects had hyper-
tension, and 2 had elevated insulin concentrations. The other
N363S carriers were healthy elderly individuals and showed
no signs or symptoms of CR.
A 1-mg DST, carried out to assess differences in GC sen-
sitivity, showed no differences in early morning post-DEX
cortisol concentrations. Because 1 mg may be a relatively
high dose (93% of the subjects suppressed to a level #50
nmol/L), we also carried out a 0.25-mg DST. In this exper-
iment, post-DEX cortisol concentrations showed a much
broader range than after 1 mg DEX (Huizenga et al., 1997,
submitted). The decease in early morning cortisol levels (D
cortisol) was significantly greater in N363S carriers than in
controls. The absolute post-DEX cortisol levels also were
lower in N363S carriers, but this difference was not statisti-
cally significant.
Another parameter for the sensitivity to exogenously ad-
ministered GCs is the fasting insulin concentration before
TABLE 3a. Insulin concentrations in controls (n 5 178) and N363S carriers (n 5 10) before and after 1 mg of DEX
Controls N363S carriers
P-valuea
Mean SE Mean SE
Fasting insulin (mU/L) 11.8 0.39 11.2 1.69 0.34
Post DEX insulin (mU/L) 17.6 0.67 23.5 5.19 0.08
D insulin (mU/L) 5.84 0.57 12.3 4.09 ,0.01
a Test for the difference between controls and N363S carriers, adjusted for BMI. Subjects with fasting insulin more than 25 mU/L were left
out of the calculation; 2 N363S carriers and 20 controls were excluded.
TABLE 3b. Insulin concentrations in controls (n 5 127) and N363S carriers (n 5 7) before and after 0.25 mg of DEX
Controls N363S carriers
P-valuea
Mean SE Mean SE
Fasting insulin (mU/L) 14.8 0.46 13.7 2.29 0.16
Post DEX insulin (mU/L) 13.7 0.51 15.5 2.83 0.69
D insulin(mU/L) 21.10 0.36 1.80 1.98 0.03
Fasting glucose (mmol/L) 5.60 0.06 5.40 0.29 0.26
Post DEX glucose (mmol/L) 5.48 0.05 5.50 0.25 0.75
D glucose (mmol/L) 20.12 0.04 0.07 0.09 0.19
a Test for the difference between controls and N363S carriers, adjusted for BMI. Subjects with fasting insulin more than 25 mU/L or fasting
glucose more than 7.8 nmol/L were left out of the calculation; 1 N363S carrier and 26 controls were excluded.
FIG. 2. Mean values and SD for BMD in the lumbar spine and the
femoral neck in controls and N363S carriers, expressed as Z-scores.
There is a trend towards lower BMD in the lumbar spine in N363S
carriers, compared with controls (Z-scores: 20.48 in N363S carriers
vs. 0.02 in controls, P 5 0.08). There are no differences in feroral neck
BMD between the two groups (P 5 0.67).
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and after DEX administration. It has been recognized for a
long time that GCs impair insulin-mediated glucose metab-
olism and induce insulin resistance (19). In this study, fasting
insulin levels before DEX were similar in the two groups, but
in response to the administration of 1 mg DEX, there was a
significantly larger increase in the serum insulin levels in
N363S carriers than in controls. After the administration of
0.25 mg DEX, there was a slight drop in insulin concentra-
tions in the control group, whereas in the N363S carriers,
mean insulin concentrations rose. It seems that in controls,
0.25 mg DEX is not sufficient to induce insulin resistance,
whereas in the N363S carriers, this low dose of DEX forces
the insulin concentrations to increase, to maintain a normal
plasma glucose concentration. These data support the as-
sumption that N363S carriers have an increased sensitivity to
GCs.
With respect to the potential long-term effects of the codon
363 mutation, three parameters were investigated: BMI,
blood pressure, and BMD. GCs are involved in the syndrome
of abdominal obesity caused by stimulatory effects on lipid
accumulation in adipose tissue (20). Patients with Cushing’s
syndrome have a centripetal fat distribution, resulting in a
higher BMI. This seems to be caused by an increased li-
poprotein lipase activity in combination with a lowered ca-
pacity for fat mobilization in the central regions (21). The net
effect of hypercortisolemia is an increase at triglyceride stor-
age in visceral adipocytes (22). At the second examination,
the N363S carriers had a significantly higher BMI than con-
trols, whereas at the first examination, there was a trend
towards a higher BMI in the N363S carriers. The higher BMI
observed in in these persons supports the view that they are
more sensitive to effects of GCs. There were, however, no
FIG. 3. GR characteristics in peripheral blood mononuclear leuco-
cytes in 41 randomly selected controls and 9 N363S carriers. A,
Number of receptors in controls and N363S carriers obtained from
whole-cell DEX-binding assays. There is no difference between
controls and N363S carriers in number of receptors per cell (n 5
7056 6 200 in controls; n 5 7242 6 645 in N363S carriers, P , 0.72).
B, Ligand affinity of the receptors (Kd) in controls and N363S
carriers obtained from whole-cell DEX-binding assays. There is no
difference in Kd between controls and N363S carriers (Kd 5 10.6 6
0.63 in controls; Kd 5 8.5 6 1.14 in N363S carriers, P , 0.17). C,
Concentrations of DEX necessary to achieve IC50 in mitogen-in-
duced proliferation assays in controls and N363S carriers. There
are no differences in IC50 values between controls and N363S
carriers (IC50 5 47.7 6 9.6 in controls; IC50 5 21.8 6 6.4 in N363S
carriers, P , 0.23).
FIG. 4. Transcriptional activation of an MMTV-LUC reporter gene by
the wild-type receptor (closed circles) and the codon 363 mutant (open
circles). Data are the average of three separate transfection assays,
each performed in duplicate. At concentrations of DEX between 0 and
100 nmol/L, the capacity of the N363S variant to activate the tran-
scription from the MMTV promotor was unaltered, compared with the
wild-type GR.
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differences in blood pressure between the two groups, nei-
ther at the first nor at the second examination.
It is well known that patients under treatment with GCs
show a reduced bone mass and an increased fracture risk.
GCs have been found to influence bone and calcium metab-
olism at several levels (23, 24). The effects of GCs on BMD are
more profound on trabecular bone than on cortical bone (24).
The data from the present investigation indeed demonstrate
a lower BMD in the lumbar spine of the N363S carriers,
compared with control subjects. However, this difference in
BMD did not reach statistical significance. In the femoral
neck, there were no differences in BMD between the groups.
Other investigations previously have found the N363S
polymorphism in a CR patient, who also showed a splice-site
deletion (10), and in the small-cell long-cancer cell lines
DMS-79 (25) and COR L24 (26). These authors found no
significant difference in the capacity of this variant GR, rel-
ative to the wild-type, to activate transcription of the CAT
gene in an MMTV-driven reporter construct after transfec-
tion into COS-1 cells. Our own results, using the more sen-
sitive MMTV-LUC system, also do not indicate a difference
between N363S and wild-type GR in this respect. Apart from
transcriptional activation, GR also is involved in transcrip-
tional repression of target genes. It does so either by binding
directly to so-called negative glucocorticoid-responsive ele-
ments (27, 28) or via interactions with factors such as acti-
vating protein-1 (AP-1) (29, 30) or nuclear factor-kB (21–23),
thereby preventing these factors from activating their target
genes. Cotransfection experiments have shown that the
codon 363 variant has an unaltered capacity to repress target
genes via negative glucocorticoid-responsive elements or via
the above mentioned transcription factors (31).
Our results of the whole-cell DEX-binding assays demon-
strate no differences between the variant- and the wild-type
GR in this respect, but because the mutation is located in the
N-terminal part of the GR, no alterations in the number of
receptors or the ligand binding capacity in peripheral mono-
nuclear leucocytes from N363S carriers were expected. The
mitogen-induced proliferation assay, on the other hand, re-
flects the cellular response to GCs (32). One would expect to
find alterations in the suppressibility of mitogen-stimulated
thymidine incorporation in cultured leucocytes from N363S
carriers. Indeed, a trend towards lower IC50 values in the
N363S carriers, compared with controls, was observed; but
these differences did not reach statistical significance, prob-
ably as a result of the wide range of values obtained in
controls.
In summary, we have shown significant effects of the
N363S mutation on changes in insulin and cortisol levels
after the administration of DEX, indicating increased sensi-
tivity to acutely increased GC levels. Long-term effects of
increased sensitivity to endogenous GCs (which might be
partly compensated by counterregulatory mechanisms)
could be reflected in the trends towards increased BMI and
decreased BMD in trabecular bone. In this connection, it is of
interest that about 5% of the patients treated with GCs de-
velop severe side effects soon after starting the therapy;
N363S carriers might be included in this subpopulation. The
apparent discrepancy between these in vivo effects and our
inability to confirm this increased sensitivity to GCs in vitro
is likely to be caused by the earlier-mentioned broad spec-
trum of regulatory mechanisms in which GCs and their re-
ceptors are involved. We showed earlier that GR mutations
can effect transcriptional activation and repression differ-
ently (31). It could well be that COS-1 cells lack the tran-
scription factors determining the effect of the N363S muta-
tion in vivo and that this is an impediment for the study of
subtle effects of this mutation in vitro.
Finally, our results may indicate that this polymorphism
is linked to an additional genetic alteration in a gene of which
the product is involved in the observed phenotypic differ-
ences. This yet-unknown factor might interact with the GR
protein to exert its effect. However, for diagnostic purposes,
the recognition of a point mutation in the GR gene linked to
a phenotypic difference may prove very useful, whether this
may solely, in part, or not at all be a consequence of altered
GR function. A next step will be to investigate whether the
codon 363 polymorphism might predict an increased sensi-
tivity to the development of early and/or serious side effects
during therapy with GCs.
In conclusion, our findings show that in vivo, the codon 363
variant of the GR is associated with an increased sensitivity
to GCs in the direct response to exogenously administered
DEX. BMI and BMD might also be effected by this variant
GR. The molecular basis for this increased sensitivity remains
to be elucidated.
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